(Q51035386)

27 March 2018

title

Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy. (English)

1 reference

27 March 2018

1 reference

Lindsey Enewold

1

1 reference

27 March 2018

Ann M Geiger

series ordinal

2

1 reference

27 March 2018

JoAnne Zujewski

series ordinal

3

1 reference

27 March 2018

Linda C Harlan

series ordinal

4

1 reference

27 March 2018

language of work or name

English

0 references

publication date

10 April 2015

1 reference

27 March 2018

Breast Cancer Research and Treatment

published in

1 reference

27 March 2018

volume

151

1 reference

27 March 2018

issue

1

1 reference

27 March 2018

page(s)

149-156

1 reference

27 March 2018

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

Who gets genomic testing for breast cancer recurrence risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

Trial assessing individualized options for treatment for breast cancer: the TAILORx trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3366-7

10.1007/S10549-015-3366-7

21 January 2018

Identifiers

DOI

1 reference

27 March 2018

1 reference

27 March 2018